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 Positional cloning identified Ifgga2 and Ifgga4 as inhibitor
genes of fatty liver.
 The expression of the human orthologue IRGM is sig-
nificantly lower in individuals with NAFLD.
 IFGGA2 interacts with ATGL and co-localizes with this
lipase at lipid droplets.
 IFGGA2 increases the amount of LC3B on lipid droplets.
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The genetic basis of non-alcoholic fatty liver
disease remains incompletely defined.
Herein, we identified members of the
immunity-related GTPase family in mice and
humans that act as regulators of hepatic fat
accumulation, with links to autophagy.
Overexpression of the gene Ifgga2 was
shown to reduce hepatic lipid storage and
could be a therapeutic target for the treat-
ment of fatty liver disease.
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JournalSee Editorial, pages 749–751Background & Aims: Currently, only a few genetic variants it associated with lipid droplets. Pulldown experiments and pro-
explain the heritability of fatty liver disease. Quantitative trait
loci (QTL) analysis of mouse strains has identified the suscepti-
bility locus Ltg/NZO (liver triglycerides from New Zealand obese
[NZO] alleles) on chromosome 18 as associating with increased
hepatic triglycerides. Herein, we aimed to identify genomic
variants responsible for this association.
Methods: Recombinant congenic mice carrying 5.3 Mbp of Ltg/
NZO were fed a high-fat diet and characterized for liver fat. Bio-
informatic analysis, mRNA profiles and electrophoretic mobility
shift assays were performed to identify genes responsible for the
Ltg/NZO phenotype. Candidate genes were manipulated in vivo by
injecting specificmicroRNAs intoC57BL/6mice. Pulldowncoupled
with mass spectrometry-based proteomics and immunoprecipi-
tation were performed to identify interaction partners of IFGGA2.
Results: Through positional cloning, we identified 2 immunity-
related GTPases (Ifgga2, Ifgga4) that prevent hepatic lipid storage.
Expression of both murine genes and the human orthologue IRGM
was significantly lower in fatty livers. Accordingly, liver-specific
suppression of either Ifgga2 or Ifgga4 led to a 3–4-fold greater in-
crease in hepatic fat content. In the liver of low-fat diet-fed mice,
IFGGA2 localized to endosomes/lysosomes,while on a high-fat dietmiRNA; NAFLD.




of Hepatology 2teomics identified the lipase ATGL as a binding partner of IFGGA2
which was confirmed by co-immunoprecipitation. Both proteins
partially co-localized with the autophagic marker LC3B. Ifgga2
suppression in hepatocytes reduced the amount of LC3B-II,
whereas overexpression of Ifgga2 increased the association of
LC3B with lipid droplets and decreased triglyceride storage.
Conclusion: IFGGA2 interacts with ATGL and protects against
hepatic steatosis, most likely by enhancing the binding of LC3B to
lipid droplets.
Lay summary: The genetic basis of non-alcoholic fatty liver
disease remains incompletely defined. Herein, we identified
members of the immunity-related GTPase family in mice and
humans that act as regulators of hepatic fat accumulation, with
links to autophagy. Overexpression of the gene Ifgga2was shown
to reduce hepatic lipid storage and could be a therapeutic target
for the treatment of fatty liver disease.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The prevalence of obesity is increasing globally. Excessive he-
patic deposition of triglycerides is termed hepatic steatosis,
which ranges from simple steatosis through fibrosis, non-
alcoholic steatohepatitis to cirrhosis.1 Non-alcoholic fatty liver
disease (NAFLD) is strongly associated with metabolic abnor-
malities such as insulin resistance, fasting hyperglycemia and
altered hepatokines.2
The cause of NAFLD is multifactorial including genetic and
environmental factors.3 Several human studies have emphasized020 vol. 73 j 771–782
Research Article NAFLD and Alcohol-Related Liver Diseasesthe highly heritable nature of the disease.4,5 Polymorphisms in
PNPLA35–7 and TM6SF28 are considered to be major genetic de-
terminants of NAFLD susceptibility. However, the identified ge-
netic variants explain only a small proportion of the risk of
NAFLD. Thus, various factors such as epigenetic mechanisms and
gene-gene interactions must be considered when looking at
heritability in the general population.9
A genome-wide scan of mouse outcross populations that
differ in their phenotype enables the identification of quantita-
tive trait loci (QTL): genomic segments conferring susceptibility
to several metabolic traits. Additionally, positional cloning en-
ables introgression of an identified QTL into a specific mouse
background to finally verify pathogenic genes such as Tsc210 and
Ifi202b.,11 To identify common gene variants responsible for
metabolic traits, e.g. hepatic fat accumulation, the Collective
Diabetes Cross of the German Center for Diabetes Research (DZD)
was performed. This is a comprehensive linkage study of an
intercross of the New Zealand obese (NZO) mouse and lean
strains (C57BL/6 [B6], DBA, C3H, 129P2), which differ in their
diabetes susceptibility.12 The NZO mouse, characterized by
adiposity, insulin resistance and hyperglycemia, is an ideal model
to provide further insights into the genetic nature of the human
metabolic syndrome.11,13
The aim of the current study was to identify genomic variants
responsible for the susceptibility locus Ltg/NZO (liver tri-
glycerides from NZO alleles) on chromosome 18, which associ-
ates with elevated hepatic lipids. We show that Ifgga2 und Ifgga4
are the most likely candidates mediating the Ltg/NZO phenotype.
The hepatic expression of both genes and the human orthologue
IRGM (immunity-related GTPase M) were markedly reduced in
livers of NZO-allele carriers and patients with NAFLD, respec-
tively. IFGGA2 interacts with the lipase ATGL which could be
responsible for preventing ectopic fat accumulation in the liver.
Materials and methods
Animals
The generation of the F1 and N2 mice and housing was
described.12 Recombinant congenic mice (RCS) were repeatedly
backcrossed to the NZO strain. RCS (N/N vs. N/B) selected for Ltg/
NZO (5.3 Mbp) were bred by repeated backcrossing of mice (N/B)
with NZO females and characterized in the F4.N10 generation.
Siblings were intercrossed to generate homozygous mice (N/N vs.
B/B, F8.N9). The Ltg/NZO locus was also transferred to a B6
background and characterized in F2.N8. At 3 weeks of age, ani-
mals received high-fat diet (HFD) (D12451, Research Diets Inc.).
Animal experiments were performed referring to the ARRIVE
guidelines and approved by the ethics committee of the State
Agency of Environment, Health, and Consumer Protection (State
of Brandenburg, Germany, 2347-21-2012, 2347-10-2014 and
2347-33-2017) and Ethics Committee of the State Ministry of
Agriculture, Nutrition and Forestry (State of North Rhine-
Westphalia, Germany, 84-02.04.2013.A118).
Genotyping
Genomic DNA-isolation from mouse tails and genotyping was
performed as described12 with self-designed KASP assays (LGC)
according to manufacturer's recommendations (Table S2).
Haplogroup analysis
Haplogroup analysis was performed as described.14,15 In brief,
mouse single nucleotide polymorphisms (SNPs) were used772 Journal of Hepatology 2(https://www.sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1303).
The chromosomal region was dissected into intervals (250 kb) to
determine the frequency of polymorphic SNPs between mouse
strains.Gene expression analysis
Total RNA was isolated using miRNeasy Micro Kit (Qiagen) or
RNeasy Mini Kits (Qiagen), cDNA prepared by M-MLV Reverse
Transcriptase-Kit (Promega). Hydrolysis probes were applied for
quantitative reverse transcription PCR (qRT-PCR). Actb, Ppia or
HPRT were used as reference genes.
Gene expression analysis of potential miR-Ifgga2 target genes
was performed using the universal probe library (UPL, Roche;
Table S3). Relative gene expression was analyzed using the DCt
method.16Microarray analysis
Genome-wide expression analysis was performed by OakLabs
GmbH (Germany) applying SurePrint G3 Mouse GE 8x60k
Microarray gene chips (Agilent Technologies). Results of analysis
are available on GEO: GSE146721 and GSE146724.Recombinant viruses
Specific micro RNAs (miRNAs or miR) targeting Ifgga2 or Ifgga4
were designed using BLOCK-iTTM RNAi Designer tool (Thermo
Fisher Scientific). Each engineered pre-miRNA double-stranded
DNA oligonucleotide was subcloned into the pcDNA6.2-GW/
EmGFP-miR vector (BLOCK-iTTM Pol II miR RNAi Expression
Vector Kit, (Invitrogen)). The miRNA expression cassette was
cloned into the pdsAAV-LP1-EGFPmut for liver-specific over-
expression under the control of the LP1 promoter.17 Within he-
patocytes, the pre-miRNA forms an intramolecular loop structure
similar to endogenous pre-miRNAs and is processed by Dicer
into the mature miRNA. Recombinant viruses (Vigene Biosci-
ence; 5 × 1011 viral genomes) were injected into the tail vein of
B6 mice (8 weeks).Plasma and supernatant analysis
Triglyceride, glycerol (TR0100, Sigma-Aldrich) and NEFA (NEFA-
HR(2), Wako Chemicals GmbH) were measured in plasma and
supernatant of liver explants and insulin concentration in plasma
by ELISA (80-Insmsu-E01, ALPCO Diagnostics) following manu-
facturer's protocol.18Non-invasive quantification of liver fat by CT
Liver fat content was measured by CT (Hitachi-Aloka LCT-200) as
described.19Detection of triglycerides in liver and hepatocytes
Triglycerides were quantified enzymatically using RandoxTR-210
(Randox).12 In brief, livers and McArdle hepatocytes or primary
hepatocytes were homogenized in 10 mmol/l sodium dihy-
drogen phosphate, 1 mmol/l EDTA and 1% (v/v) polyoxyethylene-
10-tridecyl ether and incubated for 5 min at 70C. After centri-
fugation (4C) supernatant was diluted 1:10, incubated at 70C
for 5 min and then placed on ice for 5 min before being centri-
fuged again. Clear supernatant was used for the enzymatic assay.020 vol. 73 j 771–782
Quantification of hepatic lipids by liquid chromatography-
mass spectrometry
Liver tissue was homogenized and equivalents of 1 or 0.5 mg
were subjected to lipid extraction using methanol/chloroform
(2:1, v:v) for quantification of ceramides and sphingomyelins or
diacylglycerols (DAGs), respectively. Ceramides and sphingo-
myelins were measured in tandem mass spectrometry mode as
described.20 DAGs were analyzed in mass spectrometry mode
monitoring the following [M+Na]+ ions: C15:0/C15:0 DAG (m/z
563.465), C32:0 DAG (m/z 591.496), C34:2 DAG (m/z 615.496),
C16:0/C18:1 DAG (m/z 617.512), C17:0/C17:0-d5 DAG (m/z
624.559), C36:4 DAG (m/z 639.496), C36:3 DAG (m/z 641.512) and
C36:2 DAG (m/z 643.527).
Identification of putative regulatory SNPs/Indels
To determine promoter or enhancer regions (2 kb or 50 kb
down-/upstream) we utilized histone modification datasets
(GSM100140, GSM769014 and GSM769015). Within these puta-
tive regulatory regions, genetic variants (SNPs/Indels) between
parental strains (Wellcome Trust Sanger Institute, REL-1505)
were combined with position weight matrices (PWM) from the
JASPER database.21 Thereby, genetic variants in potential tran-
scription factor binding sites (TFBS) were identified. TFBS were
predicted by R version 3.4 and the package TFBS Tools.22
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was carried out using
32P-end-labeled double-stranded DNA oligos and nuclear extracts
from HEK293T cells overexpressing HA-mFoxo1 or fromwild-type
cells. Oligos for enhancer variants were annealed and labeled at
50end. For binding reactions, 5 lg of nuclear extract were pre-
incubated in EMSA binding buffer (10 mM Tris-HCl pH 8.0, 50
mMKCl,10% glycerol, 2mMDTT, 2mMEDTA,1mMMgCl2, 0.1mg/
ml BSA, 0.1 lg/ll poly dI.dC) for 20 min on ice. Complex formation
was initiated by adding 1 ll labeled DNA probe. After 30 min in-
cubation at 25C samples were directly loaded on a 5% native PAA-
gel. Dried gels were visualized by autoradiography.
Transfection of cells and staining
McArdle or HeLa cells were seeded on poly-L-lysine coated cover
slips and cultured in DMEM (4.5 g/l glucose, Life Technologies)
containing 10% FCS until reaching a confluency of 60–70%.
McArdle hepatocytes were transfected with plasmids by using
Viromer Red (Lipocalyx) according to manufacturer's in-
structions. For induction of lipid droplet synthesis, 24 h after
transfection, cells were incubated with 50 lM of lipid complex
(oleic acid:taurocholic acid; 1.95:0.5 mM, Sigma) with or without
2 lg BODIPY in DMEM (4.5 g/L glucose) with 10% FCS. After 8 h,
cells were fixed and stained as described.18
Plasmid transfection into HeLa cells was performed with
Lipofectamine (Invitrogen) according to manufacturer's protocol,
after 24 h fixed and stained as described.18
Primary and secondary antibodies and dilutions used for
immunostaining are listed in Table S4.
Isolation and transfection of primary hepatocytes
Primary hepatocytes were isolated as described.23 Cells were
cultured in Williams E Mediumwith 4% FCS (Biochrome), 100 nM
Dexamethason, 0.5 nM insulin for 4 h. Afterwards, medium wasJournal of Hepatology 2changed to Williams E Medium without supplements and small
interfering RNA (siRNA) transfection was performed (10 nmol,
Dharmacon) using INTERFERin (VWR). After overnight incuba-
tion, transfection mediumwas replaced by Oleat-BSA complex or
BSA alone in culture medium to induce lipid droplet synthesis for
additional 24 h before harvesting.
Ex vivo autophagic flux
Autophagic flux in liver explants was assessed as described.24 In
brief, explants were incubated in DMEM ± 10% FBS containing
lysosomal inhibitors leupeptin (Sigma; 200 lM) and NH4Cl
(Merck; 20 mM) incubated for 2 h at 37C and lysed.
Subcellular fractionation of livers and protein localization
profile
Isolation of hepatic cellular fractions of mice and peptide analysis
was published.25 Mass spectrometry-based proteomics data are
available online (http://nafld-organellemap.org).
Isolation of lipid droplets of McArdle hepatocytes
After transfection cells were incubated with lipid complex and
the droplet fraction was isolated as described.26
Proteomic analysis
Proteins were eluted from Chromotek GFP-Trap beads by boiling
in SDS lysis buffer containing 2% (w/v) SDS, 100 mM Tris-HCl (pH
8.5) for 5 min at 95C. Proteome preparation was performed by
the StageTip (iST) method.27 Raw mass spectrometry data were
processed with MaxQuant version 1.6.1.13 using default settings
(false discovery rate 0.01, oxidized methionine and acetylation
[protein N-term] as variable modifications, and carbamido-
methyl as fixed modification). Label-free quantitation (LFQ) and
“Match between runs” were enabled.
Determination of protein concentration
Tissue lysates were prepared in RIPA buffer and cells lysates in
20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
TritonX-100, 2.5 mM NaPP, 1 mM b-glycerolphosphat, 1 mM
Na3VO4, 1 mM NaF and protein concentrations detected with
PierceTM BCATM Protein Assay Kit (Thermo Scientific) as
described.18
Western blot
Western blotting was performed as described.18 Dilutions of
primary and secondary antibodies are listed in Table S5.
Co-immunoprecipitation
Immunoprecipitation of IFGGA2-GFP or IRGM-Myc was per-
formed by GFP- or Myc-Trap beads (Chromotek) (Table S5).
Histology and H&E staining
Paraffin sections were stained with antibodies (Table S4). H&E
staining of sections was performed as described.28
Human liver samples
The human study (registered clinical trial, NCT01477957) was
conducted in accordance with the Declaration of Helsinki as
reported.29020 vol. 73 j 771–782 773
Research Article NAFLD and Alcohol-Related Liver DiseasesStatistical analysis
Animal number was calculated by a priori power analysis. Sta-
tistical analysis of 2 groups was performed by unpaired Student's
t test or unpaired t test with Welch's correction. One-way anal-
ysis of variance (ANOVA) with Kruskal-Wallis testing was used
for comparisons of more than 2 groups. p <0.05 was regarded as






















































































































Fig. 1. Identification of a susceptibility locus for fatty liver on chromosome 18
revealed a QTL on chromosome 18. LOD score curves for liver weight and triglyce
significance calculated with 1,000 permutations. (B) Identification of the critical re
weight and triglyceride concentrations of RCS Ltg/NZO.5.3N/N (n = 9) and Ltg/NZO.
12) (F8.N9). Data analyzed by unpaired t test with Welch's correction and presente
week-old mice stained for PLIN2 (green) and TO-PRO (blue, nuclei) as well as H&
Zealand obese; QTL, quantitative trait loci. (This figure appears in color on the w
774 Journal of Hepatology 2For further details regarding the materials and methods used,
please refer to the CTAT.
Results
Identification of Ltg/NZO, a fatty liver locus
In the Collective Diabetes Cross project, 4 leanmouse strainswere
crossed with the obese NZO strain, followed by genome-wide





























































































































. (A) Genome-wide linkage analysis of (NZOxB6)N2 population for liver weight
rides. Solid horizontal (p <0.01) and dashed lines (p <0.05) indicate threshold of
gion of Ltg/NZO (red box) and liver triglycerides in (NZOxB6)N2 mice. (C,E) Liver
5.3N/B (n = 18) (F4.N10) as well as Ltg/NZO.5.3N/N (n = 12) and Ltg/NZO.5.3B/B (n =
d as mean ± SD. **p <0.01; ***p <0.001. (D,F) Histology of liver sections from 12-
E staining. B6, C57BL/6; Ltg/NZO, liver triglycerides from NZO alleles; NZO, New
eb.)
020 vol. 73 j 771–782
weight and higher triglyceride levels on HFD in comparison to the
other strains (Fig. S1A). Genome-wide linkage analysis identified
an exclusive QTL for liver weight (Fig. 1A) and liver triglycerides
(Fig. S1B) on chromosome 18 (LOD score of 8.0 and 6.8, respec-
tively; Fig.1A). N2mice homozygous atmarker rs4231907 (17 cM/
64.9 Mbp) had elevated liver weight and triglyceride content
compared to heterozygous mice (Fig. S1C). Thus, the locus was
designated Ltg/NZO (liver triglycerides from NZO alleles).
Fine-mapping and characterization of Ltg/NZO
Positional cloning was performed to identify the critical segment
of Ltg/NZO (Fig. 1B). The highest hepatic triglyceride concentra-
tion was detected in RCS homozygous (N/N) between 58-63.3
Mbp. Mice carrying the critical region of 5.3 Mbp in a homo- (Ltg/
NZO.5.3N/N, Ltg/NZO.5.3B/B) or heterozygous (Ltg/NZO.5.3N/B)
manner were generated. Ltg/NZO.5.3N/N showed increased liver
weight and significantly elevated liver triglyceride levels (Fig. 1C)
and larger lipid droplets indicated by PLIN2 and H&E staining
(Fig. 1D) in comparison to Ltg/NZO.5.3N/B mice. The same char-
acteristics were observed after an overnight fast without any
impact on plasma parameters (Table S1). Overall DAG concen-
trations and specific DAG species were induced in Ltg/NZO.5.3N/N
compared to Ltg/NZO.5.3N/B mice; concentrations of ceramides
and sphingomyelins were not altered (Fig. S1D,E). Comparing
mice harboring homozygous alleles at the critical Ltg/NZO locus
revealed a stronger difference in hepatic triglyceride accumula-
tion (Fig. 1E,F). On the genetic B6-background, Ltg/NZON/N
resulted in significantly higher hepatic fat content in comparison
to Ltg/NZOB/B, indicating that Ltg/NZO acts independently of
adiposity (Fig. S2A–C).
Identification of immunity-related GTPases as responsible
gene variants
The region spanning 58–63.3 Mbp of Ltg/NZO harbors 106 an-
notated genes and gene models (NCBI). To identify the respon-
sible gene(s), we included sequence and expression data from
other backcross populations, genome-wide expression data, and
genomic sequence information ((NZOxDBA)N2, (NZOxC3H)N2
and (NZOx129P2)N2).12 In the (NZOxC3H)N2 progeny, liver
weight and triglycerides (LOD score 13.6) were also increased by
NZO alleles at 63 Mbp on chromosome 18. In the (NZOxDBA)N2
progeny, liver weight showed significant associations after
adjusting for blood glucose as a covariate (LOD 6.3). The
(NZOx129P2)N2 progeny did not show a QTL on chromosome 18
(Fig. S3A), suggesting that genetic variance in Ltg/NZO is caused
by alleles identical between B6, C3H and DBA mice, but different
to 129P2 and NZO mice. Based on this assumption, a haplotype
analysis of the critical region was generated by using SNP in-
formation from the Wellcome Trust Sanger Institute.30,31 The QTL
was dissected into regions that are identical by descent between
NZO and 129P2 vs. B6-, C3H- and DBA-polymorphic regions. The
number of polymorphic SNPs were determined for each 250
kb.14 Regions exceeding a threshold of 100 SNPs/window were
considered as polymorphic according to B6, C3H, DBA s NZO,
129P2 (Fig. 2A). Only genes fulfilling these criteria were consid-
ered as candidates, reducing the number to 45 genes.
Next, we implemented transcriptome data from livers of all 5
parental strains. Three genes were differentially expressed and
only 2 of them (Ifgga2, Ifgga4) were located within the critical
haplotype block. The transcriptome of Ltg/NZO.5.3N/N and Ltg/
NZO.5.3N/B livers revealed 6 differentially expressed genesJournal of Hepatology 2(Fig. 2B). The final overlap resulted in candidate genes Ifgga2
(Gm4951) and Ifgga4 (RIKEN cDNA F830016B08Rik) (Fig. S3B),
members of the family of immunity-related GTPases (IRG).
Expression of Ifgga2 and Ifgga4 was higher in livers of B6, DBA
and C3H compared to NZO and 129P2 mice (Fig. 2C). Similarly,
Ltg/NZO.5.3N/N showed a significantly lower hepatic expression of
Ifgga2 and Ifgga4 in comparison to Ltg/NZO.5.3N/B by 5- and 12-
fold and to Ltg/NZO.5.3B/B mice by 13- and 41-fold, respectively
(Fig. S3C, Fig. 2D).
A Foxo1 binding site appears to be responsible for strain-
specific expression of the Irg gene cluster
Next, we investigated the molecular cause for the reduced
expression of Ifgga2 and Ifgga4 in NZO compared to B6 livers. We
assumed a common factorwithin a cis-regulatory region upstream
of Ifgga2 as the genetic cause for the strain-specific gene regulation
of the cluster (Fig. S3D). Transcription factors often bind to
nucleosome-depleted regions which are flanked by nucleosomes
carrying H3K4me1 and H3K27ac marks.32 By combining data ob-
tained by chromatin immunoprecipitation sequencing (ChIP-seq)
from ENCODE33 and PWM, we identified an activated enhancer
harboring a Foxo1 binding motif containing a single nucleotide
deletion at position 60,211,556 bp (Build 38) in NZO and 129P2 but
not in the other strains (Fig. 2E). Although the deletion was not
located in the core sequence, the capacity of Foxo1 to bind to its
motif is reduced as shown by EMSA in nuclear extracts of HEK293
cells overexpressing Foxo1 (Fig. 2F) and could thereby be causative
for the observed hepatic expression pattern for Ifgga2 and Ifgga4.
Ifgga2 suppression in mice increases hepatic fat storage
To test whether the lower abundance of IRGs is causative for the
increased hepatic lipid accumulation induced by Ltg/NZO, Ifgga2
and Ifgga4were downregulated specifically in livers of B6mice bya
virus expressing a designedmiRNAwhich is processedwithin cells
like an endogenous miRNA and targets Ifgga2 (Fig. 3A) or Ifgga4
(Fig. S4A). AAV-miR-Ifgga2 or AAV-miR-Ifgga4 significantly sup-
pressed their expression compared to AAV-control mice 8 weeks
after virus injection (Fig. 3B; Fig. S4B). This suppression resulted in
a 4-fold or 3-fold greater increase in hepatic fat content compared
to control, respectively, according to CT analysis (Fig. 3C; Fig. S4C),
as well as the detection of increased hepatic triglyceride levels
(Fig. 3D; Fig. S4D). The increased hepatic fat content was accom-
panied by larger lipid droplets as indicated by PLIN2 and H&E
staining (Fig. 3E; Fig. S4E). Supporting these findings, primary he-
patocytes accumulated significantly more triglycerides than con-
trol cells upon Ifgga2 knockdown and lipid loading (Fig. 3F). In
order to test if the designed miRNA of Ifgga2 targets other mRNAs
which could theoretically be responsible for the observed pheno-
type, we performed an in silico analysis to predict mRNA targets.
We identified 11 potential targets whichwere not altered between
the livers of AAV-control and AAV-miR-Ifgga2mice (Fig. S5).
Subcellular localization of Ifgga2
The cellular localization of IFGGA2 was investigated in sub-
fractions derived from livers of B6 mice fed a low-fat diet (LFD)
or HFD. We used the data generated by a mass-spectrometric
workflow developed to monitor abundance and cellular distri-
butions of ~6,000 hepatic proteins.25 IFGGA4 was not identified
in the dataset. IFGGA2 displayed a lysosomal/endosomal profile
on LFD and was mainly present in the lipid droplet fraction on
HFD (Fig. 4A). This observation was confirmed by020 vol. 73 j 771–782 775
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Fig. 2. Fine-mapping of the Ltg/NZO locus in different NZO crosses. (A) Haplotype map of SNPs within the critical region of Ltg/NZO (58-63.3 Mbp). Black line:
total SNPs (all SNPs annotated for B6 reference genome with calls for C3H, DBA, 129P2 and NZO); red line: SNPs according to B6, C3H, DBAsNZO, 129P2. QTL was
dissected into windows of 250 kb. Red boxes indicate 100 SNPs per window polymorphic according to B6, C3H, DBAsNZO, 129P2. (B) Differentially expressed
genes of parental strains and RCS that are higher (blue line) or lower (red line) in NZO. (C) Hepatic expression of Ifgga2 and Ifgga4 in parental strains (normalized
to Eef2, Kruskal-Wallis test; n = 3–5) and (D) RCS (normalized to Ppia, unpaired t test with Welch's correction; n = 12). Data presented as mean ± SD. (E) Alteration
of Foxo1 binding motif in an active enhancer marked by histone modifications. (F) EMSA in HEK293 cells. Data not marked with the same letter are significantly
different. ***p <0.001. B6, C57BL/6; Ltg/NZO, liver triglycerides from NZO alleles; NZO, New Zealand obese; SNPs, single nucleotide polymorphisms. (This figure
appears in color on the web.)
Research Article NAFLD and Alcohol-Related Liver Diseasesimmunocytochemistry of untreated and lipid-loaded McArdle
hepatocytes expressing IFGGA2. In the absence of oleic acid:-
taurocholic acid complex (hereinafter referred to as oleate) in the
culture medium, IFGGA2-Myc was detected in intracellular
membranes and partially co-localized with endosomal markers776 Journal of Hepatology 2(Rab18, Fig. 4B; Rab11 and transferrin receptor, Fig. S6A). Also, in
HeLa cells, IFGGA2-Myc showed a partial overlap with LAMP1
and the transferrin receptor (Fig. S6B). In oleate treated cells (8
h), IFGGA2-GFP localized on the lipid droplet surface as indicated
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Fig. 3. In vivo downregulation of Ifgga2 in the liver elevates fat storage. (A) Sequence of miRNA and its Ifgga2 targeted sequence. (B) Hepatic expression of
Ifgga2 in AAV-control or AAV-miR-Ifgga2 mice (n = 8; normalized to Ppia). (C) Changes of liver fat detected by CT (n = 16) and (D) hepatic triglycerides (n = 8) 8
weeks after virus injection. Data analyzed by unpaired t test with Welch's correction and presented as mean ± SD. (E) Liver sections of virus-treated mice stained
for PLIN2 (green, TO-PRO (blue)) and with H&E. (F) Triglycerides in primary hepatocytes transfected with indicated siRNA and treated ± BSA-Oleate complex. Data
analyzed by Kruskal-Wallis test and presented as mean ± SD. **p <0.001; ***p <0.001. AAV, adeno-associated virus; miRNA, microRNA; siRNA, small interfering
RNA. (This figure appears in color on the web.)Interaction of IFGGA2 and ATGL
To gain insights into cellular functions and associated proteins for
IFGGA2, we performed a pulldown experiment followed by mass
spectrometry-based proteomics of McArdle hepatocytes over-
expressing IFGGA2-GFP ± oleate. Several putative binding partners
of IFGGA2 were identified. The lipase ATGL showed a significant
enrichment in the pulldown from oleate-treated cells (Fig. 5A,
Fig. S7), which was confirmed by co-immunoprecipitation exper-
iments of hepatocytes overexpressing IFGGA2-GFP and ATGL-His.
Obviously, the interaction of IFGGA2 and ATGL was more
pronounced after oleate treatment (Fig. 5B). Similarly, immuno-
cytochemical staining showed a co-localization of IFGGA2 and
ATGL on the surface of lipid droplets after lipid load (Fig. 5C).
IFGGA2 expression elevates the amount of the autophagy
marker LC3B on lipid droplets
As earlier studies described that members of the IRG family34 as
well as ATGL35 are involved in processes of autophagy, we tested
if IFGGA2 induces the degradation of lipids by lipophagy. IFGGA2
is located at the surface of lipid droplets upon lipid load and
partially co-localized with LC3B (Fig. 5D). In control cells, 32.5%
of lipid droplets displayed a positive LC3B signal, whereas
IFGGA2-Myc-expressing cells exhibited 71.1% lipid droplets with
an LC3B association (Fig. 5E), indicating that IFGGA2 enhanced
LC3B-binding to lipid droplets. In response to treatment with
oleate followed by a 24 h incubation in serum-free medium,
McArdle hepatocytes overexpressing IFGGA2-GFP or ATGL-His
stored significantly lower levels of triglycerides than control
cells (Fig. 5F), suggesting that appropriate IFGGA2 expressionJournal of Hepatology 2might protect against hepatic steatosis. Furthermore, in lipid
droplet fractions of IFGGA2-GFP expressing McArdle hepato-
cytes, LC3B-II, ATGL, CGI-58 were more abundant in comparison
to cells lacking IFGGA2 (Fig. S8A). This difference was more
pronounced after serum starvation, thus under conditions when
more IFGGA2-GFP was present in the lipid droplet fraction
(Fig. S8B). Fig. S9 shows the comparison of the subcellular dis-
tribution of IFGGA2 and LC3B in the liver fractions of mice kept
on LFD or HFD for 3 and 12 weeks. LC3B was mainly detected in
lysosomal/endosomal fractions and both proteins show a higher
abundance in the lipid droplet fraction in response to 3 weeks
HFD feeding than on LFD. In contrast, after 12 weeks on HFD,
IFGGA2 and LC3B differ in their localization; only IFGGA2 dis-
appears from the intracellular membranes and is more or less
exclusively detectable on lipid droplets (Fig. S9).
Tendency towards decreased lipophagy after suppression of
IFGGA2
In order to test if IFGGA2 induces lipophagy, its expression was
downregulated in primary hepatocytes via a specific siRNA
(Fig. S10A) and cells were treated without serum ± the autophagy
inhibitor BafilomycinA for 2 h. BafilomycinA increased the LC3B-II
signal intensity in control cells, whereas this effect was weaker in
si-Ifgga2 transfected cells. The evaluation of autophagic flux by
calculating the ratio of LC3B-II of serum-free plus BafilomycinA
and serum-free conditionsprovidedevidence for a lowerdegreeof
autophagy after downregulation of Ifgga2, however this effect did
not reach significance. No clear results were detected for other
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Fig. 4. Hepatic localization of IFGGA2 upon lipid challenge. (A) Diet-
dependent changes of IFGGA2 localization in liver fractions. Mice on LFD
(white), mice on HFD (black). (B) Staining of IFGGA2-Myc transfected McArdle
hepatocytes under basal conditions for IFGGA2-Myc (green) and Rab18 (red).
(C) Staining of PLIN2 (red) in IFGGA2-GFP (green) transfected McArdle hepa-
tocytes after lipid load. HFD, high-fat diet; LFD, low-fat diet. (This figure
appears in color on the web.)
Research Article NAFLD and Alcohol-Related Liver Diseasestreatment with serum-free medium plus BafilomycinA was a
tendency towards an elevated p62 content visible in si-Ifgga2 cells
(Fig. 6B). In addition, liver explants of AAV-miR-Ifgga2 mice were
either incubated with serum-containing or with serum-free me-
dium ± Leupeptin/NH4Cl, inhibitors of autophagy. The LC3B-II
concentrations of control samples were increased overall, but
were not significantly higher in AAV-control than in AAV-miR-
Ifgga2 explants (Fig. 6C, Fig. S10B,C). In livers of Ltg/NZO.5.3N/N, the
amount of LC3B-II was significantly lower compared to Ltg/
NZO.5.3N/Bmice (Fig. 6D, Fig. S11). However, p62 and ATG5 did not
show differences. Thus, we cannot conclusively claim that IFGGA2
influences the autophagy rate.Obese patients with NAFLD exhibit low expression of the
human orthologue IRGM
Humans express 2 IRG genes, IRGC (immunity-related GTPase
cinema) and IRGM on chromosomes 19 and 5, respectively. The
human genomic segment on chromosome 5 is syntenic to the Irg
gene cluster on murine chromosome 18 where IRGM maps only778 Journal of Hepatology 280 kb away from the closest syntenic marker Dctn4 (Fig. 7A)36.
Therefore, IRGM appears to be the most plausible human
orthologue of Ifgga2 and Ifgga4. Additionally, expression analysis
in liver biopsies of obese patients with NAFLD and healthy lean
controls29 showed no difference in IRGC expression between the
groups, but the expression of IRGM was lower in patients with
NAFLD compared to healthy controls (Fig. 7B). Thus, IRGM
expression is also negatively correlated with hepatic fat content
in humans (Pearson correlation: r = −0.327; p = 0.092).
Interestingly, the human IRGMprotein interactswith ATGL in a
similar way to the murine IFGGA2, as demonstrated by the co-
immunoprecipitation shown in Fig. 7C, which supports the
assumption that the IRGM gene is the human orthologue of Ifgga2.
Discussion
A novel fatty liver locus (Ltg/NZO) was identified wherein the
NZO allele is linked to increased hepatic fat content. The IRGs
Ifgga2 and Ifgga4 are the most likely candidates mediating the
phenotype. They were markedly suppressed in livers of NZO
allele carriers presumably due to a single nucleotide deletion in a
Foxo1-binding motif within an enhancer upstream of Ifgga2.
Downregulation of either Ifgga2 or Ifgga4 in B6 mice increased
hepatic fat accumulation and overexpression of Ifgga2 in
McArdle hepatocytes decreased fat storage. These findings
provide direct functional evidence for the important role of
Ifgga2 and Ifgga4 in regulating ectopic fat storage. The potential
mechanism might be mediated via the interaction of IFGGA2
with the lipase ATGL and an increased association of LC3B with
lipid droplets upon its overexpression.
The identification of disease-associated QTL and the subse-
quent positional cloning is a powerful non-hypothesis driven
approach to identify candidate genes for metabolic traits.12 Here,
a genome-wide linkage analysis revealed a single QTL for liver
weight and liver triglycerides in mice of (NZOxB6)N2 progeny. As
causative genes of Ltg/NZO, Ifgga2 and Ifgga4 (human orthologue
IRGM)37 were identified. Direct functional evidence that suffi-
cient Ifgga2 expression prevents fatty liver development was
provided by its overexpression in McArdle hepatocytes which
resulted in reduced triglyceride storage. Correspondingly,
downregulation of Ifgga2 or Ifgga4 in the liver increased hepatic
fat content, thereby phenocopying NZO and Ltg/NZO.5.3N/N mice.
The cause of the reduced expression of Ifgga2 and Ifgga4 in
NZO mice appears to be a single nucleotide deletion in a Foxo1-
binding motif in the NZO genome within an active enhancer
element upstream of Ifgga2. In line with this, we identified a
putative active enhancer element (ENCODE) 50 kb upstream of
IRGM showing multiple Foxo1-binding motifs in the human
genome (Fig. S12).
We hypothesize that IFGGA2 associates with membranes
containing LC3B and that a lipid load of cells or the feeding of
HFD enhances the interaction of IFGGA2 and ATGL. The data
indicate that IFGGA2 brings ATGL near to LC3B and induces lip-
ophagy through this interaction (Fig. 7D). Our hypothesis is
based on the following facts: (i) Overexpression of Ifgga2 in he-
patocytes increased association of LC3B with lipid droplets,
whereas suppression of Ifgga2 resulted in a lower abundance of
LC3B-II. (ii) In subcellular fractions, IFGGA2 and LC3B associated
within the same endosomal/lysosomal fractions; upon lipid load
and HFD, IFGGA2 and to a lesser extent LC3B translocated to lipid
droplets. (iii) Irgm1 has been described as playing a crucial role in
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Fig. 5. Interaction of IFGGA2 with ATGL and localization of IFGGA2 and LC3B upon lipid load. (A) Volcano plot of mass spectrometry-based proteomics of GFP-
pulldown of McArdle hepatocytes transfected with IFGGA2-GFP ± oleate. (B) Co-immunoprecipitation experiment of co-transfected McArdle hepatocytes. (C)
Staining of IFGGA2-GFP (green) and ATGL-His (red) in lipid-loaded McArdle hepatocytes. (D) Staining of IFGGA2-Myc (green) and LC3B (red) in McArdle he-
patocytes after lipid load. Bodipy visualizes lipid droplets (white). (E) Quantification of LC3B-positive lipid droplets dependent on the amount of IFGGA2 in
McArdle hepatocytes. Data analyzed by unpaired t test with Welch's correction and presented as mean ± SD. (F) Triglyceride levels in transfected McArdle
hepatocytes overexpressing either pEGFP, IFGGA2-GFP or ATGL-His after lipid load and fasting (n = 8). Data analyzed by Kruskal-Wallis test and presented as
mean ± SD. *p <0.05; ***p <0.001. (This figure appears in color on the web.)(iv) IFGGA2 interacts with ATGL, a known inducer of lipophagy in
the liver.38 ATGL contains a LC3B-interacting region and its
binding to autophagosomes/LC3B-II supports the translocation of
ATGL to the surface of lipid droplets and enhances its activity.38
Autophagy is an intracellular pathway that targets – besides
other intracellular components – lipids (lipophagy) to the lyso-
somes for degradation. Autophagy is increased in lean compared
to obese mice, as indicated by the enhanced conversion of LC3B-I
to LC3B-II, preventing the development of hepatic steatosis and
insulin resistance.39 In fact, suppression of Ifgga2 expression in
primary hepatocytes slightly reduced the formation of LC3B-II
(Fig. 6A), liver explants of mice in which Ifgga2 expression was
downregulated exhibited a lower concentration of LC3B-II
(Fig. 6C), and livers of Ltg/NZO.5.3 N/N mice with low expression
of Ifgga2 had a lower concentration of LC3B-II (Fig. 6D; Fig. S11).
Moreover, the human orthologue IRGM was reported to induce
autophagy by facilitating the recruitment of Syntaxin17 to
autophagosomes by interacting with LC3B.40 Therefore, it might
be possible that the crosstalk of IFGGA2, LC3B and ATGL pro-
motes lipophagy. However, it is also likely that IFGGA2 binding to
ATGL modifies its activity by other mechanisms. Firstly, theJournal of Hepatology 2association of IFGGA2 with ATGL could interrupt the binding of
the lipase to the inhibitors G0S2 or HILPDA, which have been
shown to directly interact with ATGL.41 Secondly, IFGGA2 could
affect sorting of proteins to lipid droplets, thereby limiting their
growth. Thirdly, IFGGA2 could interfere with the action of en-
zymes of the glycerol-3-phosphate pathway which not only act
at the endoplasmic reticulum but also associate directly with
lipid droplets (GPAT4, DGAT1, DGAT2, AGPAT3 and lipin) and
mediate triglyceride biosynthesis.42 Further experiments and
biochemical analyses are required to clarify how IFGGA2 acts at
the lipid droplet and decreases ectopic fat storage in the liver.
Expression of IRGM is significantly reduced in the livers of
obese individuals with NAFLD compared to control individuals.
Two human cohorts showed that IRGM variants are associated
with an increased risk of NAFLD. The studies indicated that the
frequency of the risk allele is highly depended on ethnic groups;
45.6% carry the risk allele in a cohort of Han-Chinese43 but only
2.5% in an European cohort.44 The less functional TT-variant of
IRGM (rs10065172) was linked to an increased risk of steatosis in
obese Italian children.44 Furthermore, the downregulation of





























































Fig. 7. Expression of human IRGC and IRGM genes. (A) Cluster of immunity-related GTPases on mouse chromosome 18 and human chromosome 5. (B)
Expression of IRGC and IRGM in liver biopsies of lean controls (Control, n = 7) and humans with non-alcoholic fatty liver disease (NAFLD, n = 11). Data were
normalized to HPRT, analyzed by unpaired t test and presented as mean ± SD. *p <0.05. (C) Co-immunoprecipitation of co-transfected McArdle hepatocytes. (D)
Scheme of the hypothesis how the interaction of the proteins IFGGA2, LC3B and ATGL promotes lipophagy. NAFLD, non-alcoholic fatty liver disease. (This figure
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Fig. 6. Suppression of IFGGA2 reduces autophagy. (A) Western blotting and quantification of autophagy proteins in siRNA-transfected primary hepatocytes
treated ± BafilomycinA for 2 h (n = 3). (B) Analysis and quantification of p62 in siRNA-transfected hepatocytes treated ± BafilomycinA for 24 h (n = 2–3). (C) Ex vivo
flux assay from liver explants of AAV-Control (n = 4) and AAV-miR-Ifgga2 (n = 3) mice. Quantification also includes data of Fig. S11. Data are expressed as fold of
control. (D) Analysis of autophagy proteins in livers of Ltg/NZO.5.3N/N (n = 10) and Ltg/NZO.5.3N/B (n = 11) mice after 16 h fasting. Quantification also includes data of
Fig. S12. Data are expressed as fold of control (N/N), analyzed by unpaired t test with Welch's correction and presented as mean ± SD. ***p <0.001. AAV, adeno-
associated virus; Ltg/NZO, liver triglycerides from New Zealand obese alleles; miR, microRNA; siRNA, small interfering RNA.
Research Article NAFLD and Alcohol-Related Liver Diseasesaccompanied by increased lipid accumulation.43 Thus, com-
pounds that can increase the expression of IRGM could have
therapeutic potential for fatty liver diseases.
In conclusion, our data show that Ifgga2 and Ifgga4 and their
human orthologue IRGM are key players that protect against
hepatic steatosis.
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